Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 306

Sort by

Sort Order Select

Journal Articles

Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection

Alissa Visram, Dirk Larson, Aaron D Norman, Angela Dispenzieri, David L Murray, Robert A Kyle, S. Vincent Rajkumar, Susan L. Slager, Shaji K Kumar, Celine M. Vachon

Blood blood.2024025415.

https://doi.org/10.1182/blood.2024025415

Published: 2024

Includes: Supplemental data

Journal Articles

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Rahul Banerjee, Rachael Sexton, Andrew J. Cowan, Aaron S. Rosenberg, Sikander Ailawadhi, S. Vincent Rajkumar, Shaji K Kumar, Angela Dispenzieri, Sagar Lonial, Brian G.M. Durie, Paul G. Richardson, Saad Z Usmani, Antje Hoering, Robert Z Orlowski

Blood blood.2024025939.

https://doi.org/10.1182/blood.2024025939

Published: 2024

Includes: Supplemental data

Journal Articles

Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy

Rajshekhar Chakraborty, Saurabh Zanwar, Ute Hegenbart, Divaya Bhutani, Morie A Gertz, Angela Dispenzieri, Shaji K Kumar, Anita D'Souza, Anannya Patwari, Andrew J Cowan, GuiZhen Chen, Paolo Milani, Giovanni Palladini, Vaishali Sanchorawala, Geethika Bodanapu, Stefan Schönland, Suzanne Lentzsch, Eli Muchtar

Blood blood.2024025899.

https://doi.org/10.1182/blood.2024025899

Published: 2024

Includes: Supplemental data

Journal Articles

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

Blood (2023) 142 (22): 1871–1878.

https://doi.org/10.1182/blood.2023021187

Published: 2023

Includes: Supplemental data

Journal Articles

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Wilson I. Gonsalves, Natalia Neparidze, Jacob B. Allred, Shaji K Kumar, Joel M. Reid, Geoffrey Shapiro, Brian A. Costello, Richard Piekarz, Rachid C. Baz, Srinivas Devarakonda

Blood (2022) 140 (Supplement 1): 7315–7316.

https://doi.org/10.1182/blood-2022-164966

Published: 2022

Journal Articles

Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide

Blood (2022) 140 (Supplement 1): 9998–9999.

https://doi.org/10.1182/blood-2022-160368

Published: 2022

Journal Articles

Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes

Blood (2022) 140 (Supplement 1): 10142–10143.

https://doi.org/10.1182/blood-2022-169046

Published: 2022

Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Blood (2022) 140 (Supplement 1): 10133–10136.

https://doi.org/10.1182/blood-2022-163555

Published: 2022

Journal Articles

Current Testing Practices for t(11;14) Rearrangements in Patients with Newly Diagnosed Multiple Myeloma in the United States

Linda B. Baughn, Elizabeth S. Mearns, Michael Nixon, Vivek S. Chopra, Allicia Girvan, R. Frank Cornell, Jayeta Saxena, Bethany M. Slifko, Jordan Clark, Shaji K Kumar

Blood (2022) 140 (Supplement 1): 10114–10115.

https://doi.org/10.1182/blood-2022-158076

Published: 2022

Journal Articles

Single-Cell Dissection of Primary Quadruplet- and Triplet-Resistant Multiple Myeloma

Moritz Binder, Amelia Mazzone, Jenna A. Fernandez, Wazim Mohammed Ismail, S. Vincent Rajkumar, Alexandre Gaspar Maia, Shaji K Kumar

Blood (2022) 140 (Supplement 1): 9978–9979.

https://doi.org/10.1182/blood-2022-162679

Published: 2022

Journal Articles

AI-Enabled Screening for Drug Repurposing in Monoclonal Gammopathy of Undetermined Significance

Alexander J Ryu, Shaji K Kumar, Angela Dispenzieri, Robert A. Kyle, S. Vincent Rajkumar, Thomas C Kingsley

Blood (2022) 140 (Supplement 1): 7842–7843.

https://doi.org/10.1182/blood-2022-169376

Published: 2022

Journal Articles

Validation of a Novel Rac1 Inhibitor As Potent Secdrug Against Activating Ras Mutant and Drug-Resistant Multiple Myeloma

Salsabil Ahmed, Suman Mazumder, Lisa Wiesen, Neeraj Sharma, Ujjal Kumar Mukherjee, Shaji K Kumar, Linda B. Baughn, Brian G. Van Ness, Amit Kumar Mitra

Blood (2022) 140 (Supplement 1): 4249–4250.

https://doi.org/10.1182/blood-2022-164501

Published: 2022

Journal Articles

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Shaji K Kumar, Melissa Alsina, Betsy Laplant, Ashraf Z. Badros, Al-Ola Abdallah, Rafat Abonour, Erik J Asmus, Binod Dhakal, Cara A. Rosenbaum, Daniel Egan, Manisha Bhutani, Andrzej Jakubowiak, Brian G.M. Durie

Blood (2022) 140 (Supplement 1): 1830–1832.

https://doi.org/10.1182/blood-2022-168930

Published: 2022

Journal Articles

Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 2347–2348.

https://doi.org/10.1182/blood-2022-167430

Published: 2022

Journal Articles

Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma

Paula Rodríguez Otero, Nisha S. Joseph, Shaji K Kumar, Hans C. Lee, Xavier Leleu, Salomon Manier, Meletios A. Dimopoulos, María Victoria Mateos, Albert Oriol, Naresh Bumma, Weiying Gong, Pourab Roy, Karen Rodriguez Lorenc, Glenn S. Kroog, Shawn M. Sarkaria

Blood (2022) 140 (Supplement 1): 4444–4446.

https://doi.org/10.1182/blood-2022-157713

Published: 2022

Journal Articles

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Shaji K Kumar, Craig C Hofmeister, Noa Biran, Gurbakhash Kaur, Jing Christine Ye, Jeffrey A. Zonder, Umar Syed, Jennifer Yesil, Karen Woolley, George Mulligan, Hearn J. Cho

Blood (2022) 140 (Supplement 1): 4434–4435.

https://doi.org/10.1182/blood-2022-163737

Published: 2022

Journal Articles

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4401–4404.

https://doi.org/10.1182/blood-2022-167008

Published: 2022

Journal Articles

Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes

Blood (2022) 140 (Supplement 1): 8092–8093.

https://doi.org/10.1182/blood-2022-164617

Published: 2022

Journal Articles

Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7141–7143.

https://doi.org/10.1182/blood-2022-163746

Published: 2022

Journal Articles

Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib

Reyka G. Jayasinghe, George Mulligan, April Cook, Mark Hamilton, Sacha Gnjatic, Seunghee Kim-Schulze, Hearn J. Cho, Shaji K Kumar

Blood (2022) 140 (Supplement 1): 7090–7091.

https://doi.org/10.1182/blood-2022-167462

Published: 2022

NARROW

Comparison of progression risk of monoclonal gammopathy of undetermined significance by method of detection

Dexamethasone dose intensity does not impact outcomes in newly diagnosed multiple myeloma: a secondary SWOG analysis

Prognostic impact of cytogenetic abnormalities by FISH in AL amyloidosis with daratumumab-based frontline therapy

Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas

A Multicenter Phase I Dose-Escalation Trial of a Novel Glutaminase Inhibitor Telaglenastat in Combination with Carfilzomib and Dexamethasone in Relapsed and Refractory Multiple Myeloma

Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide

Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma - MRD Negativity and Survival Outcomes

Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis

Current Testing Practices for t(11;14) Rearrangements in Patients with Newly Diagnosed Multiple Myeloma in the United States

Single-Cell Dissection of Primary Quadruplet- and Triplet-Resistant Multiple Myeloma

AI-Enabled Screening for Drug Repurposing in Monoclonal Gammopathy of Undetermined Significance

Validation of a Novel Rac1 Inhibitor As Potent Secdrug Against Activating Ras Mutant and Drug-Resistant Multiple Myeloma

Fixed Duration Therapy with Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone for High Risk Smoldering Multiple Myeloma-Results of the Ascent Trial

Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma

Trial in Progress: REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase Ib Multi-Cohort Study of Combination Regimens for Patients with Relapsed/Refractory Multiple Myeloma

The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

A Phase 1 First-in-Human Study of Abbv-383, a BCMA × CD3 Bispecific T-Cell-Redirecting Antibody, As Monotherapy in Patients with Relapsed/Refractory Multiple Myeloma

Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes

Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma

Myeloma Developing Regimens Using Genomics (MyDRUG): Longitudinal Single-Cell Transcriptional Landscape of the Myeloma and Immune Microenvironment in Relapsed/Refractory Multiple Myeloma Patients Treated with MEK-Inhibitor, Cobimetinib

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only